Su1385 EFFICACY OF PROBIOTICS COMBINED WITH BISMUTH QUADRUBLE THERAPY ON HELICOBACTER PYLORI TREATMENT: A RANDOMIZED CONTROLLED STUDY

Liu, Xinlei; Ma, Yihan; Yang, Jinlin; Wang, Yiping; Zhao, Yin

doi:10.1016/s0016-5085(20)32137-5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten RCTs were included [78][79][80][81][82][83][84][85][86][87] from China, [78,79,83,84,86] Iran, [82,87] Spain, [80] Thailand, [81] and Italy. [85] Five of these used triple therapy plus compound probiotics, [79,[82][83][84]87] three augmented Lactobacillus, [80,81,85] one augmented Bifidobacterium, [78] and one augmented Clostridium butyricum. [86] Duration of treatment varied between 7 days and 30 days.…”

Section: Evidence Profilementioning

confidence: 99%

2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment

Zhou

Lü

Song

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

Background: Helicobacter pylori (H. pylori) infection is an infectious disease with a prevalence rate of up to 50% worldwide. It can cause indigestion, gastritis, peptic ulcer, and gastric cancer. H. pylori eradication treatment can effectively control disease progression and reduce the risk of the above conditions. However, the escalating trend of antibiotic resistance presents a global challenge for H. pylori eradication. We aim to provide guidance on pharmacological treatment of H. pylori infection. Methods: This clinical practice guideline is developed following the World Health Organization's recommended process, adopting Grading of Recommendations Assessment, Development and Evaluation in assessing evidence quality, and utilizing Evidence to Decision framework to formulate clinical recommendations, minimizing bias and increasing transparency of the clinical practice guideline development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and The Appraisal of Guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline's completeness and transparency. Results: Though decreasing in developed countries, the prevalence of H. pylori remains high in developing countries, causing a major public health burden. This clinical practice guideline contains 12 recommendations concerning pharmacological treatment for H. pylori eradication. Among them, it is worth highlighting that bismuth preparations are inexpensive, safe, and effective, consequently making bismuth quadruple therapy a preferred choice for initial and rescue treatment. In empirical treatment, highdose dual therapy is equally effective compared with bismuth quadruple therapy. Conclusions: The 12 recommendations in this clinical practice guideline are formed with consideration for stakeholders' values and preferences, resource use, feasibility, and acceptability. Recommendations are generalizable to resource limited settings with similar antibiotic resistance pattern as China, and lower middle-income countries facing comparable sociological and technical challenges.

show abstract